Similar articles

• Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.

  Albertson PC. Albertson PC. Eur Urol. 2009 Jun;55(6):1331-2. doi: 10.1016/j.eururo.2009.02.029. Epub 2009 Mar 6. Eur Urol. 2009. PMID: 19286304 No abstract available.
• Active surveillance for prostate cancer: has the time finally come?

  Aragon-Ching JB. Aragon-Ching JB. J Clin Oncol. 2010 Jun 1;28(16):e265-6; author reply e267. doi: 10.1200/JCO.2010.28.1584. Epub 2010 Apr 20. J Clin Oncol. 2010. PMID: 20406916 No abstract available.
• What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database.

  Barocas DA, Cowan JE, Smith JA Jr, Carroll PR; CaPSURE Investigators. Barocas DA, et al. J Urol. 2008 Oct;180(4):1330-4; discussion 1334-5. doi: 10.1016/j.juro.2008.06.019. Epub 2008 Aug 15. J Urol. 2008. PMID: 18707731
• The prostate specific antigen. Its use as a tumor marker for prostate cancer.

  Kantoff PW, Talcott JA. Kantoff PW, et al. Hematol Oncol Clin North Am. 1994 Jun;8(3):555-72. Hematol Oncol Clin North Am. 1994. PMID: 8707772 Review.
• Treatment of stage A1 prostate cancer: the case for treatment.

  Bahnson RR. Bahnson RR. Semin Urol. 1993 May;11(2):54-7. Semin Urol. 1993. PMID: 7689739 Review. No abstract available.